Trials / Completed
CompletedNCT04720378
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
A Phase 1, Multi-Center, Open-Label, Safety and Tolerability Study of Intravenous Administration of ST266 in Subjects With Confirmed COVID-19 Infection
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The primary aim of the study is to evaluate the safety and tolerability of open-label ST266 given to subjects with confirmed COVID-19 infection through IV administration once a day of 5 consecutive days.
Detailed description
This clinical trial will utilize a 3+3 enrollment design with sentinel approach.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ST266 | 1X ST266 |
Timeline
- Start date
- 2021-05-30
- Primary completion
- 2022-05-03
- Completion
- 2022-05-03
- First posted
- 2021-01-22
- Last updated
- 2022-06-15
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04720378. Inclusion in this directory is not an endorsement.